Indian Pharma Sector’s Growth Prospects in 2024
Indian Pharmaceutical Sector: A Promising Outlook for 2024
The Indian pharmaceutical sector is experiencing a significant upswing, propelled by a variety of factors that have led to robust earnings for domestic pharma corporations. This growth is most evident in the United States, where the generics market is flourishing, and uptake in branded markets has seen a substantial increase. The key driving forces behind this prosperity include softer raw material costs and gains in market share from recently introduced products.
Forecasted Growth in CY24
In the upcoming Calendar Year 2024 (CY24), many domestically-focused companies are anticipated to witness mid-teen growth. This optimistic outlook is based on the expected launch of new products, amplified volume growth, and a surge in demand for both generics and branded offerings. Several pharmaceutical powerhouses like Cipla, Torrent Pharma, Eris Lifesciences, and JB Chemicals are expanding their chronic disease product lines, introducing innovative therapies, and investing in capital expenditures to fortify active pharmaceutical ingredient (API) production. This strategic maneuvering is predicted to pave the way for further revenue augmentation.
Stable Operating Margins
Operating margins for these corporations are expected to remain high, hovering around 20-30% in CY24. The favorable product mix and decreased input costs are contributing to this stability. In India, business growth is projected in the high single digits in CY24. This growth is anticipated to be catalyzed by a backlog in acute demand, expansion in the chronic segment, the launch of new products, and the projected robust flu season.
US Market Prospects
The US market also portrays a promising future, with expectations of sturdy growth despite obstacles like pricing pressure, competition, and strict regulatory compliance. Factors contributing to this growth include normalization of base business prices, an expanded sales force, and the launch of new products. Companies are also undergoing restructuring to unlock shareholder value. For instance, Sanofi is planning a demerger of its over-the-counter (OTC) business, while Strides is proposing a demerger of its contract development and manufacturing organization (CDMO) business in CY24.
Positive Outlook for the Indian Pharma Industry
The positive trends in the domestic formulation business, as well as the strategies, anticipated margins, and growth prospects of specific companies, suggest an optimistic outlook for the Indian pharmaceutical industry in the coming year. US-focused pharma companies are also well-positioned for growth, thanks to normalization in demand, new launches, and stabilizing pricing pressures. These developments hint at a brighter future for the Indian pharmaceutical sector in the year ahead.
No Byline Policy
Editorial Guidelines
Corrections Policy
Source